Replies to post #590 on PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[genisi]

Vpriv head start is nearly done in the sense of capturing Cerezyme switchers during the shortage because Shire is reaching its production capacity limit and it will take at least a year before it will be able to ramp it up. GENZ is still at half production capacity and said this should improve gradually. So, not getting a priority review is not a disaster but certainly disappointing for PLX.

[surf1944]

Protalix will begin dual listing in Tel Aviv
Protalix BioTherapeutics will begin listing shares on the Tel Aviv in addition to NYSE

The Associated Press, On Monday August 30, 2010, 9:09 am EDT
Biotech company Protalix BioTherapeutics Inc. said Monday it will begin listing its shares on the Tel Aviv Stock Exchange in addition to its listing on the New York Stock Exchange Amex.

CEO David Aviezer said the company decided to list on the Tel Aviv exchange "after experiencing significant interest regarding our company from Israeli investors." The company has a partnership with Pfizer Inc. for a generic version of Genzyme's drug for the genetic disorder Gaucher disease, up for U.S. approval by February.

Protalix trades under the ticker "PLX" on the NYSE Amex. It will begin trading on the Tel Aviv Stock Exchange on Sept. 6.

The Tel Aviv Stock Exchange is open for trading Sunday through Thursday from 9:45 a.m. to 4:30 p.m. Israel time.

In premarket trading, Protalix's U.S.-listed shares rose 25 cents, or 3.3 percent, to $7.80.